SS
CRDL

SBI Securities’s Cardiol Therapeutics CRDL Stock Holding History

SBI Securities’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$641 Hold
475
– – ﹤0.01% 2802
2025
Q4 		$453 Sell
475
-1
-0.2% -$1 ﹤0.01% 2904
2025
Q3 		$509 Sell
476
-1
-0.2% -$1 ﹤0.01% 2953
2025
Q2 		$649 Buy
477
+2
+0.4% +$2 ﹤0.01% 2854
2025
Q1 		$461 Buy
475
+200
+73% +$246 ﹤0.01% 2902
2024
Q4 		$352 Buy
+275
New +$464 ﹤0.01% 3021

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SBI Securities's CRDL Position: Q1 2026 in Review

SBI Securities held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 475 shares worth $641. The position accounts for ﹤0.01% of the portfolio, ranked #2802.

SBI Securities first reported a position in CRDL in Q4 2024 and has held it in 6 quarters since. The position peaked at $649 in Q2 2025. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • SBI Securities held 475 shares of Cardiol Therapeutics worth $641 as of Q1 2026.
  • SBI Securities left its Cardiol Therapeutics share count unchanged in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2802 holding.
  • SBI Securities first reported a position in Cardiol Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Cardiol Therapeutics position peaked at $649 in Q2 2025.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.